Evidence map›Paper›PMID 42735485›Full record

ArticleEuropean journal of medicinal chemistry2026

Discovery of a brain penetrant NLRP3 inflammasome inhibitor that reduces neuropathic pain in mice.

Yiming Xu, Jannatun Namme, Liuyue Yang, Yulong Xu, Savannah Biby, Lu Qian, Tony Tuck, Ashley Gomm, Nitai Sarkar, Zheng Liu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yiming XuDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Jannatun NammeDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Liuyue YangCenter for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Yulong XuAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, United States.
Savannah BibyDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Lu QianDepartment of Pharmacology, Physiology and Biophysics, Boston University, Boston, MA, 02118, United States.
Tony TuckDepartment of Pharmacology, Physiology and Biophysics, Boston University, Boston, MA, 02118, United States.
Ashley GommGenetics and Aging Research Unit, McCane Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, United States.
Nitai SarkarDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Zheng LiuDepartment of Human & Molecular Genetics, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Sasha MurphyDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Xiang-Yang WangDepartment of Human & Molecular Genetics, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298, United States.
Julia TcwDepartment of Pharmacology, Physiology and Biophysics, Boston University, Boston, MA, 02118, United States; Bioinformatics Program, Faculty of Computing & Data Sciences, Boston University, Boston, MA, 02215, United States.
Zhu ZhouDepartment of Pharmaceutical Sciences, University of the Pacific, Stockton, CA, 95211, United States.
Rudolph TanziGenetics and Aging Research Unit, McCane Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, United States.
Can ZhangGenetics and Aging Research Unit, McCane Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, United States.
Changning WangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, United States.
Shiqian ShenCenter for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Shijun ZhangDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, United States. Electronic address: szhang2@vcu.edu.

Funding

Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's diseaseU01AG076481 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Shijun Zhang · 2022 to 2026
$7.5M
Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytesR01AG082362 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.3M
Microglia targeted interventions in prodromal Alzheimer's disease stageR01AG083941 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Julia TCW · 2023 to 2026
$3.2M
Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracersRF1AG076912 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, SHIJUN · 2023 to 2023
$1.9M
Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracersR01AG076912 · NIA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Shijun Zhang · 2026 to 2026
$625k
NIA NIH HHS R01 AG076912NIA NIH HHS R01 AG082362NIA NIH HHS R01 AG083941NIA NIH HHS RF1 AG076912NIA NIH HHS U01 AG076481
6 · The paper itself

Abstract

In our continuing campaign to discover novel inhibitors of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3), an emerging drug target that tightly regulates the innate immune responses, a 1H-1,2,3-triazole-4-carboxamide scaffold was designed and optimized. Iterative optimization led to the identification of a lead inhibitor, 22, with an IC

Identifiers

PMID42735485
PMCPMC13637552

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.